Ipsen (XPAR:IPN) Short-Term Debt: €4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:IPN Ipsen SA XPAR:IPN
96 GF Score
Price €163.00
GF Value €134.63
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Short-Term Debt?

Ipsen XPAR:IPN +0.43% 96 Short-Term Debt is €4 Mil as of Dec. 2025. GuruFocus rates XPAR:IPN with a GF Score™ of 96/100 and a GF Value™ of €134.63 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Ipsen's Short-Term Debt for the quarter that ended in Dec. 2025 was €4 Mil.

Ipsen's quarterly Short-Term Debt increased from Dec. 2024 (€1 Mil) to Jun. 2025 (€2 Mil) and increased from Jun. 2025 (€2 Mil) to Dec. 2025 (€4 Mil).

Ipsen's annual Short-Term Debt declined from Dec. 2023 (€9 Mil) to Dec. 2024 (€1 Mil) but then increased from Dec. 2024 (€1 Mil) to Dec. 2025 (€4 Mil).

Ipsen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ipsen Short-Term Debt Related Terms

Ipsen Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ipsen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Short-Term Debt Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.50 3.80 9.00 0.60 4.00

Ipsen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 17.90 0.60 2.10 4.00
XPAR:IPN
96GF Score
Ipsen SA XPAR:IPN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €4 Mil mean?
Ipsen (XPAR:IPN) has a Short-Term Debt of €4 Mil as of Dec. 2025.
Is Ipsen's Short-Term Debt too high?
Ipsen's current Short-Term Debt is €4 Mil. Overall, Ipsen has a GF Score™ of 96/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Short-Term Debt compare to ZTS and UTHR?
Ipsen's Short-Term Debt of €4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ipsen's current Short-Term Debt is €4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (XPAR:IPN) is currently considered Modestly Overvalued. The stock's GF Value™ is €134.63, compared to a current price of €163.00 — trading 21.1% above its estimated fair value. The current Short-Term Debt is €4 Mil. Ipsen's overall GF Score™ is 96/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ipsen (XPAR:IPN), the current Short-Term Debt is €4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (XPAR:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €163.00 is trading 21.1% above its estimated GF Value™ of €134.63. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for XPAR:IPN:

  • Short-Term Debt: €4 Mil
  • GF Value™: €134.63 vs. price of €163.00 (21.1% above fair value)
  • GF Score™: 96/100 with 7 warning signs

No single metric tells the full story. See the XPAR:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
96GF Score

Get the complete analysis for XPAR:IPN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€163.00
Price
€134.63
GF Value